Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Drops By 59.9%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 9,959 shares, a decrease of 59.9% from the May 31st total of 24,832 shares. Based on an average trading volume of 31,504 shares, the short-interest ratio is currently 0.3 days. Currently, 0.3% of the shares of the stock are short sold.

Institutional Investors Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC acquired a new position in shares of Pulmatrix, Inc. (NASDAQ:PULM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors and hedge funds own 11.84% of the company’s stock.

Pulmatrix Stock Up 4.3%

Shares of PULM stock opened at $1.70 on Wednesday. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $7.00. The company has a market cap of $6.21 million, a P/E ratio of -1.38 and a beta of 1.95. The business has a fifty day simple moving average of $1.38 and a 200 day simple moving average of $1.99.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).